Robin K. Avery

17.6k total citations · 5 hit papers
226 papers, 10.6k citations indexed

About

Robin K. Avery is a scholar working on Epidemiology, Infectious Diseases and Oncology. According to data from OpenAlex, Robin K. Avery has authored 226 papers receiving a total of 10.6k indexed citations (citations by other indexed papers that have themselves been cited), including 137 papers in Epidemiology, 91 papers in Infectious Diseases and 52 papers in Oncology. Recurrent topics in Robin K. Avery's work include Cytomegalovirus and herpesvirus research (82 papers), Herpesvirus Infections and Treatments (40 papers) and Polyomavirus and related diseases (38 papers). Robin K. Avery is often cited by papers focused on Cytomegalovirus and herpesvirus research (82 papers), Herpesvirus Infections and Treatments (40 papers) and Polyomavirus and related diseases (38 papers). Robin K. Avery collaborates with scholars based in United States, Canada and Thailand. Robin K. Avery's co-authors include Dorry L. Segev, Allan B. Massie, Per Ljungman, William A. Werbel, Jacqueline Garonzik‐Wang, Brian J. Boyarsky, Lorry G. Rubin, Athos Bousvaros, Marcie Tomblyn and Harry Keyserling and has published in prestigious journals such as The Lancet, JAMA and Journal of Clinical Investigation.

In The Last Decade

Robin K. Avery

219 papers receiving 10.4k citations

Hit Papers

2013 IDSA Clinical Practi... 2013 2026 2017 2021 2013 2014 2021 2021 2021 250 500 750 1000
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
    2013 1.1k citations Robin K. Avery et al. Clinical Infectious Diseases profile →
  2. Executive Summary: 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host
    2014 649 citations Robin K. Avery et al. Clinical Infectious Diseases profile →
  3. Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
    2021 590 citations Brian J. Boyarsky, William A. Werbel et al. profile →
  4. Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
    2021 340 citations Brian J. Boyarsky, William A. Werbel et al. profile →
  5. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial
    2021 167 citations Robin K. Avery, Catherine Cordonnier et al. Clinical Infectious Diseases profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Robin K. Avery 6.0k 4.7k 1.8k 1.8k 1.2k 226 10.6k
Deepali Kumar 6.8k 1.1× 3.8k 0.8× 1.5k 0.9× 1.6k 0.9× 1.2k 1.0× 233 10.0k
Atul Humar 10.6k 1.8× 4.1k 0.9× 2.9k 1.6× 2.2k 1.2× 1.6k 1.3× 275 14.4k
Raymund R. Razonable 8.1k 1.3× 3.8k 0.8× 2.3k 1.3× 1.5k 0.9× 980 0.8× 290 11.1k
José María Aguado 4.4k 0.7× 3.5k 0.7× 831 0.5× 1.9k 1.0× 764 0.6× 298 7.9k
Lindsey R. Baden 5.0k 0.8× 5.9k 1.2× 1.7k 0.9× 720 0.4× 345 0.3× 230 10.7k
Fausto Baldanti 7.1k 1.2× 5.8k 1.2× 2.0k 1.1× 736 0.4× 216 0.2× 434 12.3k
Ajit P. Limaye 5.5k 0.9× 3.1k 0.6× 2.7k 1.5× 793 0.4× 846 0.7× 182 9.3k
Asunción Moreno 5.6k 0.9× 3.9k 0.8× 550 0.3× 1.3k 0.7× 951 0.8× 257 8.2k
Hans H. Hirsch 4.9k 0.8× 6.3k 1.3× 12.7k 7.1× 1.2k 0.7× 2.6k 2.1× 384 18.8k
Mario Fernández‐Ruiz 2.1k 0.4× 1.9k 0.4× 763 0.4× 856 0.5× 448 0.4× 228 4.8k

Countries citing papers authored by Robin K. Avery

Since Specialization
Citations

This map shows the geographic impact of Robin K. Avery's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin K. Avery with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin K. Avery more than expected).

Fields of papers citing papers by Robin K. Avery

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin K. Avery. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin K. Avery. The network helps show where Robin K. Avery may publish in the future.

Co-authorship network of co-authors of Robin K. Avery

This figure shows the co-authorship network connecting the top 25 collaborators of Robin K. Avery. A scholar is included among the top collaborators of Robin K. Avery based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin K. Avery. Robin K. Avery is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hammond, Sarah P., et al.. (2024). A Multicenter Assessment of the Outcomes and Toxicities of Foscarnet for Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex in Immunocompromised Patients. Open Forum Infectious Diseases. 11(3). ofae046–ofae046. 6 indexed citations
2.
Chou, Sunwen, Drew J. Winston, Robin K. Avery, et al.. (2024). Comparative Emergence of Maribavir and Ganciclovir Resistance in a Randomized Phase 3 Clinical Trial for Treatment of Cytomegalovirus Infection. The Journal of Infectious Diseases. 231(3). e470–e477. 5 indexed citations
3.
Danziger‐Isakov, Lara, Anne Rose, Daniel Kaul, et al.. (2024). Presentation, management, and outcomes of norovirus in adult and pediatric solid organ and hematopoietic stem cell transplant recipients: A multicenter, retrospective study. Transplant Infectious Disease. 26(3). e14270–e14270.
4.
Manothummetha, Kasama, Anawin Sanguankeo, Pattama Torvorapanit, et al.. (2023). Ribavirin treatment for respiratory syncytial virus infection in patients with haematologic malignancy and haematopoietic stem cell transplant recipients: a systematic review and meta-analysis. Clinical Microbiology and Infection. 29(10). 1272–1279. 19 indexed citations
5.
Alejo, Jennifer L., Teresa Po‐Yu Chiang, Robin K. Avery, et al.. (2023). Patient‐reported outcomes after Tixagevimab and Cilgavimab pre‐exposure prophylaxis among solid organ transplant recipients: Safety, effectiveness, and perceptions of risk. Clinical Transplantation. 37(4). e14913–e14913. 5 indexed citations
6.
Permpalung, Nitipong, Teresa Po‐Yu Chiang, Robin K. Avery, et al.. (2023). Coronavirus Disease 2019–Associated Pulmonary Aspergillosis: A Noninvasive Screening Model for Additional Diagnostics. Open Forum Infectious Diseases. 10(4). ofad155–ofad155. 3 indexed citations
7.
Belga, Sara, Robin K. Avery, Christine M. Durand, et al.. (2023). Impact of recipient age on mortality among Cytomegalovirus (CMV)-seronegative lung transplant recipients with CMV-seropositive donors. The Journal of Heart and Lung Transplantation. 43(4). 615–625. 1 indexed citations
8.
Shapira, Guy, David W. Mohr, Maria Bettinotti, et al.. (2023). Genomic Markers Associated with Cytomegalovirus DNAemia in Kidney Transplant Recipients. Viruses. 15(11). 2227–2227. 1 indexed citations
9.
Permpalung, Nitipong, Tao Liang, Darin Ostrander, et al.. (2023). Invasive fungal infections after respiratory viral infections in lung transplant recipients are associated with lung allograft failure and chronic lung allograft dysfunction within 1 year. The Journal of Heart and Lung Transplantation. 42(7). 953–963. 5 indexed citations
10.
Chiang, Teresa Po‐Yu, Jennifer L. Alejo, Jonathan Mitchell, et al.. (2022). Heterologous Ad.26.COV2.S versus homologous BNT162b2/mRNA-1273 as a third dose in solid organ transplant recipients seronegative after two-dose mRNA vaccination. American Journal of Transplantation. 22(9). 2254–2260. 11 indexed citations
11.
Permpalung, Nitipong, Robin K. Avery, Hyesik Kong, et al.. (2022). Elevated cell-free DNA in respiratory viral infection and associated lung allograft dysfunction. American Journal of Transplantation. 22(11). 2560–2570. 23 indexed citations
12.
Strauss, Alexandra T., Jennifer L. Alejo, Teresa Po‐Yu Chiang, et al.. (2022). Severe acute respiratory syndrome coronavirus 2 antibody response to a third dose of homologous messenger RNA vaccination in liver transplantation recipients. Liver Transplantation. 28(8). 1393–1396. 4 indexed citations
13.
Dioverti, M. Veronica, David C. Gaston, C. Paul Morris, et al.. (2022). Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients. Open Forum Infectious Diseases. 9(6). ofac064–ofac064. 18 indexed citations
14.
Karaba, Andrew H., William A. Werbel, M. Veronica Dioverti, et al.. (2021). Interleukin‐18 and tumor necrosis factor‐α are elevated in solid organ transplant recipients with possible cytomegalovirus end‐organ disease. Transplant Infectious Disease. 23(4). e13682–e13682. 4 indexed citations
15.
Stern, Anat, Carolyn D. Alonso, Carolina García‐Vidal, et al.. (2021). Safety and efficacy of intravenously administered cidofovir in adult haematopoietic cell transplant recipients: a retrospective multicentre cohort study. Journal of Antimicrobial Chemotherapy. 76(11). 3020–3028. 12 indexed citations
16.
Jarrell, Andrew, Rachel Kruer, M. Veronica Dioverti, et al.. (2020). Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid-organ Transplant Recipients on Continuous Veno-venous Hemodialysis. Clinical Infectious Diseases. 73(1). 101–106. 10 indexed citations
17.
Cravedi, Paolo, Jesse D. Schold, Kassem Safa, et al.. (2020). The COVID‐19 pandemic: A community approach. Clinical Transplantation. 34(11). e14059–e14059. 8 indexed citations
18.
Ignatius, Elisa H., Kunbo Wang, Andrew H. Karaba, et al.. (2020). Tocilizumab for the Treatment of COVID-19 Among Hospitalized Patients: A Matched Retrospective Cohort Analysis. Open Forum Infectious Diseases. 8(1). ofaa598–ofaa598. 20 indexed citations
19.
Garibaldi, Brian T., Pali D. Shah, Gigi Liu, et al.. (2020). Clinical course of COVID-19 in a liver transplant recipient on hemodialysis and response to tocilizumab therapy: A case report. American Journal of Transplantation. 20(8). 2254–2259. 35 indexed citations
20.
Schuster, Mindy G., Angela A. Cleveland, Erik R. Dubberke, et al.. (2017). Infections in Hematopoietic Cell Transplant Recipients: Results From the Organ Transplant Infection Project, a Multicenter, Prospective, Cohort Study. Open Forum Infectious Diseases. 4(2). ofx050–ofx050. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Deepali Kumar Breakdown of academic impact, for papers by Atul Humar Breakdown of academic impact, for papers by Raymund R. Razonable Breakdown of academic impact, for papers by José María Aguado Breakdown of academic impact, for papers by Lindsey R. Baden Breakdown of academic impact, for papers by Fausto Baldanti Breakdown of academic impact, for papers by Ajit P. Limaye Breakdown of academic impact, for papers by Asunción Moreno Breakdown of academic impact, for papers by Hans H. Hirsch Breakdown of academic impact, for papers by Mario Fernández‐Ruiz
Rankless by CCL
2026